Families prescribed Monarch can now pay with digital wallets or third-party installment plans at checkout LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced expanded payment options for patients prescribed the Monarch eTNS® System, the first non-drug treatment for pediatric ADHD cleared by the U.S. Food and Drug Administration. Patients receiving a Monarch eTNS prescription can now choose from a wider range of payment methods at checkout, incl

U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal nerve U.S. launch supported by a waitlist of more than 1,500 patients, caregivers, and providers Visit www.monarch-etns.com for additional information on how to obtain the Gen 2 Monarch® device LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Lo

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts University in 2025 Foxcroft will conduct its first large mammal (canine) trial in mid-2026, using Hopewell’s LNPs WOBURN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Hopewell Therapeutics, Inc. , a Boston-based next-generation lipid nanoparticle (LNP) company (“ Hope